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Abstract
Objectives: To assess the effect of topical application of melatonin to the gingiva on salivary fluid concentrations 
of acid phosphatase, alkaline phosphatase, osteopontin, and osteocalcin.
Study Design: Cross-sectional study of 30 patients with diabetes and periodontal disease and 30 healthy subjects. 
Diabetic patients were treated with topical application of melatonin (1% orabase cream formula) once daily for 20 
days and controls with a placebo formulation.
Results: Before treatment with melatonin, diabetic patients showed significantly higher mean salivary levels of 
alkaline and acid phosphatase, osteopontin and osteocalcin than healthy subjects (P < 0.01). After treatment with 
melatonin, there was a statistically significant decrease of the gingival index (15.84± 10.3 vs 5.6 ± 5.1) and pocket 
depth (28.3 ± 19.5 vs 11.9 ± 9.0) (P < 0.001). Also, use of melatonin was associated with a significant reduction of 
the four biomarkers. Changes of salivary acid phosphatase and osteopontin correlated significantly with changes 
in the gingival index, whereas changes of alkaline phosphatase and osteopontin correlated significantly with 
changes in the pocket depth.
Conclusions: Treatment with topical melatonin was associated with an improvement in the gingival index and 
pocket depth, a reduction in salivary concentrations of acid phosphatase, alkaline phosphatase, osteopontin and 
osteocalcin. 
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Introduction
Periodontal disease is a complex condition that may 
vary from gingivitis to extreme destruction of tooth-
supporting tissue. Although bacterial infection and re-
lease of toxic bacterial products triggers a series of proc-
esses leading to damage of healthy tissues, a number of 
actions of the host’ immune response is also involved. 
However, the etiopathogenesis and pathophysiology of 
periodontal disease remains unclear. 
A response of the organism to the periodontal infection 
includes the production of several intracellular enzymes 
(1). Alkaline phosphatase and acid phosphatase are in-
tracellular enzymes present in most tissues and organs, 
particularly in bones. Some studies have shown a re-
markably increase in the activity of these enzymes in 
periodontitis and a reduction after periodontal therapy 
(2,3). Also, salivary alkaline phosphatase levels may be 
useful as a potential bone turnover marker to establish 
the diagnosis and prognosis of periodontal disease (4). 
On the other hand, periodontal tissue destruction via 
osteoclastic action results in the sequestration of bone 
specific matrix proteins, like telopeptides type I colla-
gen (5), osteocalcin (6), osteonectin (7), osteopontin (8) 
and bone phosphoprotein (9) in the gingival crevicular 
fluid, all of which have been positively associated with 
the progression of periodontal disease (10,11).
Melatonin, an indoleamine secreted by the pineal gland 
in a circadian manner, is a noteworthy free radical scav-
enger (12) and also plays an immunomodulatory role 
(13). Several studies have shown that melatonin stimu-
lates the proliferation and synthesis of type I collagen 
and promotes bone formation (14,15). Melatonin may 
have implications in diseases of the oral cavity, limiting 
tissue damage that is a result of free radicals, stimu-
lating the immune response and reducing the progres-
sive loss of alveolar bone (16,17). Previous studies of 
our group have shown the periodontal protective role of 
melatonin (18,19). 
In order to assess the usefulness of melatonin applica-
tion as a potential therapeutic strategy in periodontal 
processes, a cross-sectional study was conducted, the 
objective of which was to determine the effect of topi-
cal application of melatonin on salivary concentrations 
of alkaline phosphatase, acid phosphatase, osteocalcin 
and osteopontin in patients with diabetes and periodon-
tal disease and in a control group of healthy subjects. 
The effect of topical melatonin on changes in clinical 
parameters, including the gingival index and the pocket 
depth was also assessed.
Material and methods
-Participants
The study was carried out at the Health Center of Pinos 
Puente (Granada, Spain). A total of 30 healthy indi-
viduals of both sexes (20 men, 18 women), aged 31 to 
68 years (mean ± standard deviation, 47.0 ± 10.3 yrs) 
without periodontal disease and 30 patients  with dia-
betes and periodontal disease of both sexes (14 men, 16 
women) aged 24 to 58 years (mean 43.1 ± 12.4 yrs) were 
included in the study. There were 17 patients with type I 
diabetes and 13 with type II diabetes. All patients were 
free of medication (except for the treatment of diabetes). 
The type of periodontal disease was not an inclusion 
criterion for the study, although most patients presented 
advanced periodontitis. Other exclusion criteria includ-
ed current use of bisphosphonates, oral contraceptives, 
antibiotic treatment in the previous 6 months, and hav-
ing received (within the last 6 months) or being treated 
for diseases of the oral cavity. All healthy subjects were 
in good general health with no history of systemic dis-
ease or clinical signs of periodontal disease.
Participants were fully informed about the study and 
gave written informed consent. The study protocol was 
approved by the �thics Committee of the Faculty of Od-
ontology, University of Granada, and the code of �thics 
of the World Medical Association was observed. 
All study participants (patients and control) underwent 
an oral examination, including medical, dental, and 
caries assessments. The same dentist performed all 
examinations. Periodontograms were performed us-
ing the Florida Probe® handpiece (computerized peri-
odontal probing system). The gingival index, bleeding 
on probing, and probing depth (20) were registered in 
patients with diabetes and in healthy subjects. There-
after, patients with diabetes were treated with topical 
application of melatonin (1% orabase cream formula) 
both in the upper and lower dental arches on the sur-
faces of the attached gingiva for 20 days. Healthy 
subjects were treated with a placebo orabase cream. 
Melatonin cream (or placebo) was applied daily at 
night after routine oral hygiene. All participants were 
instructed how to use the orabase cream; it was rec-
ommended to apply the amount that fits in a regular 
toothbrush for adults per dental arch. Conventional 
periodontal treatment prior or during the study was 
not allowed. Oral examination was also performed at 
the end of treatment.
-Saliva collection
Before and after treatment, salivary samples from 
diabetic patients and healthy controls were collected. 
Patients and controls came to the School of Dentistry 
of the University of Granada at 09:00 AM after 12-h 
overnight fast. After 15 min of rest, a sample of saliva 
was obtained from each individual. In order to stimu-
late saliva production, the participants chewed a piece 
of paraffin wax for 7 min. Saliva produced during the 
first 2 min was discarded. Then, saliva was collected 
during the following 5 min, to avoid any possible con-
tamination. The patients chewed the paraffin during the 
time of saliva collection. Samples of collected saliva 
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were centrifuged at 3,000 g, 4ºC for 15 min, and then 
the clear supernatant was frozen at -80ºC until assays 
were performed.
-Analytical determinations 
The activity of acid and alkaline phosphatase in saliva 
was determined spectrometrically by the International 
Federation of Clinical Chemistry (IFCC) method on the 
Hitachi 911 Automatic Analyzer. Osteocalcin measure-
ments in saliva were made using an electrochemilumi-
nescence technique (Immulite 2000, Diagnostic Prod-
ucts Corporation, Los Angeles, CA, USA). The concen-
tration of osteopontin was determined by sandwich-type 
of a human osteopontin enzyme immunometric assay 
(�IA) kit (TiterZyme, Assay Designs, Ann Arbor, MI, 
USA) according to the manufacturer’s instructions.
-Statistical analyses
Quantitative variables are expressed as the mean ± 
standard deviation (SD). The paired Student s´ t test 
was used for the comparison of the gingival index and 
probing depth before and after topical application of 
melatonin among patients with periodontal diabetic 
disease, and the t test for independent samples for the 
comparison of salivary levels of acid phosphatase, alka-
line phosphatase, osteocalcin and osteopontin between 
the groups of diabetic patients and healthy subjects. The 
relationship between the gingival index and probing 
depth with acid phosphatase, alkaline phosphatase, os-
teocalcin and osteopontin levels in saliva was assessed 
with the Pearson s´ correlation coefficient. Statistical 
significance was set at P < 0.05. The Statistical Package 
for the Social Sciences (SPSS) (version 11.0) was used 
for the analysis of data.
Results
The comparison of salivary levels of acid and alkaline 
phosphatases, osteocalcin and osteopontin between 
diabetic patients and healthy controls before treatment 
with melatonin is shown in table 1. Patients with dia-
betes had significantly higher mean levels of salivary 
acid phosphatase (83.08 ± 6.85 vs 20.55 ± 1.99 U/L) (P 
< 0.001), alkaline phosphatase (40.51 ± 4.83 vs 7.34 ± 
1.28 U/L) (P < 0.001), osteocalcin (5.83 ± 1.41 vs 4.97 ± 
1.35 ng/mL) (P = 0.020) and osteopontin (12.49 ± 1.78 
vs 2.44 ± 0.80 µg/mL) (P < 0.001) than healthy subjects 
(Figs. 1,2).
After the application of topical melatonin, there was 
a statistically significant reduction of the gingival in-
dex (15.84 ± 10.26 vs 5.59 ± 4.08), pocket depth (28.29 
± 19.48 vs 11.9 ± 9.01) and salivary levels of alkaline 
phosphatase (40.51 ± 4.83 vs 26.88 ± 4.03 ng/mL) (P < 
0.001), acid phosphatase (83.08 ± 6.85 vs 43.2 ± 5.52) (P 
< 0.001), osteocalcin (5.83 ± 1.41 vs 5.78 ± 1.39 ng/mL) 
(P = 0.028) and osteopontin (12.49 ± 1.78 vs 8.34 ± 1.45 
µg/mL) (P < 0.001) (Table 2).
There was also a significant association between 
changes in the gingival index before and after treat-
ment with melatonin and changes in salivary levels of 
acid phosphatase (r = 0.499, P = 0.005) and osteopon-
tin (r = 0.578, P = 0.001). Changes in the pocket depth 
correlated with changes in salivary levels of alkaline 
phosphatase (r = 0.366, P = 0.047), acid phosphatase 
(r = 0.443, P = 0.014) and osteopontin (r = 0.739, P = 
0.001) (Table 3). 
Salivary Concentrations Healthy subjects (mean ± SD) 
Diabetic patients 
(mean ± SD) 
P
value*
Alkaline phosphatase, U/L 7.34 ± 1.28 40.51 ± 4.83 < 0.001 
Acid phosphatase, U/L 20.55 ± 1.99 83.08 ± 6.85 < 0.001 
Osteocalcin, ng/mL 4.97 ± 1.35 5.83 ± 1.41 0.020 
Osteopontin, µg/L 2.44 ± 0.80 12.49 ± 1.78 < 0.001 
Treatment with topical  
melatonin for 20 days Pvalue*Before (mean ± SD) After (mean ± SD) 
    Periodontal indexes    
Gingival index 15.8 ± 10.26 5.59 ± 4.08 < 0.001 
Pocket depth 28.3 ± 19.48 11.9 ± 9.01 < 0.001 
    Salivary levels    
Alkaline phosphatase, U/L 40.51 ± 4.83 26.88 ± 4.03 < 0.001 
Acid phosphatase, U/L 83.08 ± 6.85 43.2 ± 5.52 < 0.001 
Osteocalcin, ng/mL 5.83 ± 1.41 5.78 ± 1.39 0.028 
Osteopontin, µg/L 12.49 ± 1.78 8.34 ± 1.45 < 0.001 
Table 1. Comparison of patients with diabetes and healthy controls before topical gingival treat-
ment with melatonin.
*Student’s t test for independent samples.
Table 2. Comparison of gingival index, pocket depth and salivary levels of alkaline phosphatase, acid 
phosphatase, osteocalcin and osteopontin before and after topical application of melatonin.
*Paired t test.
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Fig. 1. a) Box plot of the differences in salivary osteocalcin levels between healthy subjects and dia-
betic patients before topical application of melatonin. b) Box plot of the differences in salivary osteo-
pontin between healthy subjects and diabetic patients before topical application of melatonin.
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Discussion
It has been shown that the concentration in saliva of 
some intracellular enzymes, such as 
alkaline phosphatase and acid phosphatase are elevated 
in patients with periodontal disease (20); thus, increased 
salivary levels of these enzymes are regarded as valua-
ble biochemical markers of alveolar bone destruction in 
active periodontal disease (2). Accordingly, a decrease 
in the salivary fluid levels of these enzymes would indi-
cate lower alveolar bone destruction (21,22).
Osteocalcin, a protein found in the extracellular matrix 
of bone and dentin and involved in regulating minerali-
Fig. 2. a) Box plot of the differences in salivary alkaline phosphatase levels between healthy subjects and diabetic 
patients before topical application of melatonin. b) Box plot of the differences in salivary acid phosphatase levels be-
tween healthy subjects and diabetic patients before topical application of melatonin.
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zation in the bones and teeth, is currently described as 
a specific marker of osteoblast function (23). Moreover, 
different studies have evaluated osteocalcin levels in 
crevicular fluid as a potential marker of abnormal bone 
turnover in periodontal disease progression (24). Simi-
larly, osteopontin levels in crevicular fluid have been 
considered a marker of alveolar bone destruction (25). 
The objective of this study was to evaluate the effect 
of topical application of melatonin to the gingiva on 
clinical indexes of periodontitis and salivary levels of 
phosphatases and osteocalcin and osteopontin as mark-
ers of alveolar bone status. The study population in-
cluded a group of patients with diabetes and periodontal 
disease and a group of healthy subjects. The associa-
tion between diabetes and periodontal diseases is well-
established. Diabetes is a risk factor for periodontal 
disease, with diabetic patients exhibiting an increased 
prevalence, extent and severity of gingivitis and peri-
odontitis compared to healthy adults (26). On the other 
hand, sialochemistry has been increasingly used for the 
assessment of periodontal disease indicators (27). We 
found that treatment with melatonin was associated with 
improvement in the gingival index and pocket depth, 
and a rise in salivary concentrations of acid and alka-
line phosphatases, osteocalcin and osteopontin. These 
findings suggest that melatonin may have a favourable 
effect in slowing osteoclastogenesis, improving the 
quality of alveolar bone and preventing the progression 
of periodontal disease. The protective role of melatonin 
against periodontal disease has been also demonstrated 
in other studies (28,29).
The present findings, however, should be interpreted 
taking into account some limitations of the study, in 
particular the small sample size. However, these en-
couraging preliminary findings in a reduced number 
of diabetic patients and healthy controls will hopefully 
stimulate further research to elucidate the potential use-
fulness of treatment with melatonin to improve peri-
odontal disease.
In summary, treatment with melatonin on the gingiva 
was associated with an improvement in the gingival in-
dex and pocket depth, and an increase in salivary con-
centrations of alkaline phosphatase, acid phosphatase, 
osteocalcin and osteopontin. This indicates that mela-
tonin may exert a beneficial effect on decreasing peri-
odontitis and in slowing osteoclastogenesis, improving 
the quality of alveolar bone and preventing the progres-
sion of periodontal disease.
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